These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 12616104

  • 1. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW, Kurt RA, Baher AG, Denman S, Justice L, Doran T, Gilbert M, Alvord WG, Urba WJ.
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
    Mier JW.
    J Immunother; 2003; 26(2):95-6. PubMed ID: 12616100
    [No Abstract] [Full Text] [Related]

  • 3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 4. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.
    Br J Cancer; 2003 May 06; 88(9):1346-51. PubMed ID: 12778059
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
    Westermann J, Reich G, Kopp J, Haus U, Dörken B, Pezzutto A.
    Cancer Immunol Immunother; 2001 Jan 06; 49(11):613-20. PubMed ID: 11225992
    [Abstract] [Full Text] [Related]

  • 6. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 06; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun 06; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 8. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 9. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
    Koulova L, Novik Y, Caliendo G, Wiernik P, Dutcher J.
    J Immunother; 2005 Mar 15; 28(6):576-81. PubMed ID: 16224275
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH.
    J Clin Oncol; 2003 Nov 01; 21(21):4016-26. PubMed ID: 14581425
    [Abstract] [Full Text] [Related]

  • 12. Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.
    Domingo-Musibay E, Heun JM, Nevala WK, Callstrom M, Atwell T, Galanis E, Erickson LA, Markovic SN.
    Oncologist; 2017 Sep 01; 22(9):1026-e93. PubMed ID: 28679643
    [Abstract] [Full Text] [Related]

  • 13. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.
    Clin Cancer Res; 1996 Feb 01; 2(2):319-30. PubMed ID: 9816175
    [Abstract] [Full Text] [Related]

  • 14. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ.
    J Clin Oncol; 1995 Aug 01; 13(8):1939-49. PubMed ID: 7636534
    [Abstract] [Full Text] [Related]

  • 15. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
    Vaughan MM, Moore J, Riches PG, Johnston SR, A'Hern RP, Hill ME, Eisen T, Ayliffe MJ, Thomas JM, Gore ME.
    Ann Oncol; 2000 Sep 01; 11(9):1183-9. PubMed ID: 11061616
    [Abstract] [Full Text] [Related]

  • 16. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis.
    Hotton KM, Khorsand M, Hank JA, Albertini M, Kim KM, Wilding G, Salamat MS, Larson M, Sondel P, Schiller JH.
    Cancer; 2000 Apr 15; 88(8):1892-901. PubMed ID: 10760767
    [Abstract] [Full Text] [Related]

  • 17. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
    Elias EG, Zapas JL, Beam SL, Brown SD.
    Oncology (Williston Park); 2005 Apr 15; 19(4 Suppl 2):15-8. PubMed ID: 15934495
    [Abstract] [Full Text] [Related]

  • 18. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients.
    Schaafsma MR, Falkenburg JH, Landegent JE, Duinkerken N, Osanto S, Ralph P, Kaushansky K, Wagemaker G, Van Damme J, Willemze R.
    Blood; 1991 Oct 15; 78(8):1981-7. PubMed ID: 1912580
    [Abstract] [Full Text] [Related]

  • 19. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH.
    J Immunother Emphasis Tumor Immunol; 1994 Aug 15; 16(2):132-41. PubMed ID: 7804528
    [Abstract] [Full Text] [Related]

  • 20. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P, Mengo S, Bucovec R, Brivio F, Fumagalli L, Tancini G, Gardani GS.
    In Vivo; 2003 Aug 15; 17(1):73-5. PubMed ID: 12655794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.